Ligand Pharmaceuticals (LGND) Current Deferred Revenue (2010 - 2025)

Ligand Pharmaceuticals has disclosed Current Deferred Revenue across 14 years of filings, most recently posting $111000.0 for Q2 2025.

• Current Deferred Revenue for Q2 2025 came in at $111000.0, down 90.72% year-over-year; the trailing twelve-month figure through Jun 2025 was $111000.0 (down 90.72% YoY), and the FY2024 annual result was $1.3 million, up 4.58% from the prior year.
• Current Deferred Revenue came in at $111000.0 for Q2 2025 at Ligand Pharmaceuticals, up from $101000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $25.1 million in Q1 2021 to a low of $101000.0 in Q1 2025.
• The 5-year median for Current Deferred Revenue is $1.2 million (2023), against an average of $5.8 million.
• Peak annual rise in Current Deferred Revenue reached 476.64% in 2021, while the deepest fall reached 97.78% in 2021.
• Ligand Pharmaceuticals' Current Deferred Revenue stood at $654000.0 in 2021, then sank by 45.72% to $355000.0 in 2022, then surged by 244.23% to $1.2 million in 2023, then gained by 4.58% to $1.3 million in 2024, then slumped by 91.31% to $111000.0 in 2025.
• The last three Current Deferred Revenue figures came in at $111000.0 (Q2 2025), $101000.0 (Q1 2025), and $1.3 million (Q4 2024), per Business Quant data.